Synergy of Herbal Oil Extracts/Antibiotic Combinations in Drug- Resistant Uropathogenic E. coli
Urinary tract infection (UTI) is the second most common infection worldwide and Escherichia coli (E. coli) is the chief causing pathogen. Antimicrobial resistance results into therapeutic failure. This study aimed to incrimination of E. coli as uropathogen harbouring cnf1 gene (necrotoxin virulenc...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Journal of Pure and Applied Microbiology
2020-06-01
|
Series: | Journal of Pure and Applied Microbiology |
Subjects: | |
Online Access: | https://microbiologyjournal.org/synergy-of-herbal-oil-extracts-antibiotic-combinations-in-drug-resistant-uropathogenic-e-coli/ |
Summary: | Urinary tract infection (UTI) is the second most common infection worldwide and Escherichia coli (E.
coli) is the chief causing pathogen. Antimicrobial resistance results into therapeutic failure. This study
aimed to incrimination of E. coli as uropathogen harbouring cnf1 gene (necrotoxin virulence)and
to detect the in vitro antimicrobial efficacy of several selected essential oil/antibiotic combinations
against the isolated uropathogenic E. coli. Well diffusion method was used to determine the minimal
inhibitory concentrations (MICs) to essential oils (EOs) individually. Broth micro-dilution method was
used to determine the minimal inhibitory concentrations (MICs) to antibiotics and in combinations, to
figure out the interactive efficacy of tested combinations. Necrotoxin cnf1 gene was detected by PCR
assay. E.coli was detected at a rate of 40.6% of the isolated urinary pathogens and 47.8% showed ESBL
production. In-vitro synergistic efficacy was only observed for cinnamon oil/gentamycin combination
in 100% of selected 15 tested isolates (P-value <0.001). The cnf1 virulence gene was detected in 40%
of tested isolates showing no significant correlation the conferred pattern of resistance among the
E. coli isolates. Cinnamon/gentamycin combination against drug-resistant E-coli is promising and can
pave the way for further clinical trials to formulate pharmacological combinations. |
---|---|
ISSN: | 0973-7510 2581-690X |